1272. Feasibility and Successful Enrollment in Proof-of-Concept Trials to Assess Safety and Efficacy of a Broadly Neutralizing Monoclonal Antibody, VRC01, to Prevent HIV-1 Acquisitionin in Uninfected Individuals

Srilatha Edupuganti(Emory University), Lawrence Corey(Fred Hutch Cancer Center), Myron S. Cohen(University of North Carolina at Chapel Hill), Paul Goepfert(University of Maryland, Baltimore), Allan C. deCamp(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Nidhi Kochar(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Maija Anderson(Fred Hutch Cancer Center), Simbarashe Takuva(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Emily Shava(Botswana Harvard AIDS Institute Partnership), Pamela Mukwekwerere(University of Zimbabwe), Kyle Marshall(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Shelly Karuna(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Martín Casapía(Asociación para la Conservación de la Cuenca Amazónica), Margarita Gomez Lorenzo, John R. Mascola(National Institute of Allergy and Infectious Diseases), Erica Lazarus(Norwegian Womens Public Health Association), P. Andrew(Family Health International 360), Jorge Sánchez(National University of San Marcos), David Burns(Norwegian Womens Public Health Association), Nyaradzo Mgodi(University of Zimbabwe), John Hural(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Robert De La Grecca(Infectious Disease Research Institute)
Open Forum Infectious Diseases
October 1, 2019
Cited by 0


Related Papers